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Chapter 3
Identifying disease-associated variants can improve the predictive 
models of disease risk and provide mechanistic insights into disease 
development. Coeliac disease (CD) is the only autoimmune trait with 
a known environmental trigger, which makes it an excellent model for 
studying the complexity of genetic and environmental factors in the 
development of autoimmunity. In this review, we will focus on the ge-
netic loci that have recently been associated with CD and that contain 
genes involved in innate and adaptive immunity. Some of these loci 
are shared with other immune-mediated diseases, suggesting an over-
lap of the genetic mechanisms involved in the development of such 
diseases. Some therapies, e.g. tumour necrosis factor inhibitors or a 
gluten-free diet, are already proving effective for more than one auto-
immune disease. Follow-up of individuals with a high genetic risk of 
CD and other autoimmune diseases could help to elucidate the role of 
environmental factors (such as infectious agents or alterations in the 
microbiome) and prevent disease development.
Background
that is mainly triggered and maintained by storage proteins of wheat, 
barley and rye [1]. However, inherited genetic factors also affect disease 
susceptibility as is evident from twin and family studies. Having at least 
two individuals with CD in a family increases the rate of the disease 
[2]. Monozygotic twins show a high 
concordance rate of 75% for CD development, further supporting a 
strong role for genetic factors [3]. The most dominant CD genetic risk 
factors are the genotypes encoded by the human leucocyte antigen 
(HLA) class II molecules HLA-DQ2 and HLA-DQ8. Approximately 95% 
of patients with CD carry the HLA-DQ2 allele and the remaining 5% 
carry HLA-DQ8 [4]. HLA genes are responsible for approximately 40% 
of the genetic risk for CD [5]. The other 60% of the genetic susceptibility 
to CD is shared between an unknown number of non-HLA genes, each 
of which is estimated to contribute only a small effect [6].
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Coeliac disease is triggered by dietary gluten, which leads to peptides 
passing through the epithelial barrier of the intestine into the lamina 
propria, where they can be deaminated by the enzyme tissue trans-
glutaminase (tTG). These peptides are presented by HLA class II mol-
ecules, which can lead to activation of CD4+ T-helper 1 lymphocytes 
and the resulting crypt hyperplasia and villous atrophy [1].
 Other environmental risk factors, such as infections and being 
breastfed for only a short duration, have also been proposed to play a 
role in CD development. An increased frequency of rotavirus infections 
has been associated with an increased risk of developing CD [7]. In ad-
dition, there is a complex three-way relationship between adenovirus 
12, hepatitis C virus (HCV) and the development of CD [8]. Variations in 
the incidence of CD during the season or month of birth have also been 
observed and may indicate variations in endemic viral infections, which 
could act as triggers for perinatal diseases [9]. The results of some stud-
ies have suggested that breastfeeding during the period of gluten in-
troduction can reduce the risk of developing CD by approximately 50% 
[10]. These studies were based on a retrospective cohort. Recently, a 
prospective study showed that there is no association between breast-
feeding and development of CD [11]. The only treatment for CD to date 
is a gluten-free diet, although potential new therapeutic targets, such 
as the degradation of gluten by prolyl endopeptidases, have been iden-
[12].
 Advances in serological screening, especially the appearance 
of tests to measure immunoglobulin A anti-tTG, anti-endomysial and 
anti-gliadin antibodies, have shown that the prevalence of CD has in-
creased in the last 30 years. A study conducted in Finland demon-
strated that this increase in prevalence of CD cannot be attributed to 
improved methods for detection of the disease, but that environmental 
factors are involved [13, 14]. Better screening has also provided evidence 
that CD is common in other parts of the world, including Asia and South 
America where CD was previously considered to be a rare disease 
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Fig. 1. Global prevalence of coeliac disease and four autoimmune diseases of epidemiological 
importance. Because of their similar immune aetiologies, their co-existence with each other is 
much more common than with other types of diseases [16, 90].
CD: coeliac disease, T1D: type 1 diabetes, RA: rheumatoid arthritis, UC: ulcerative colitis, CrD: 
Crohn’s disease
(Figure 1). The prevalence of CD in children in northern India is 0.32%, 
in adults in Turkey it is 1.3%, in Argentina it is 0.6% and in Brazil it is be-
tween 0.15% and 0.46% [15, 16]. The current prevalence of CD in Europe 
and the USA is 1–3% [16]. However, the highest prevalence of CD has 
been reported in Saharawi children (5.6%), probably due to genetic 
factors and the rapidly changing dietary habits of this population [17].
 The co-existence of CD with other immune-mediated diseases 
is evident from epidemiological studies [18], and recent genetic stud-
ies have provided evidence of shared genetic risk factors between CD 
and, for example, Crohn’s disease (CrD), ulcerative colitis (UC), rheu-
matoid arthritis (RA) and type 1 diabetes (T1D) [19].
 In this review, we will discuss the genetics of CD, and the ge-
netic factors and associated pathways shared with CrD, RA, T1D and 
UC. We will also consider the relevance of identifying shared genetic 
pathways and their potential for future therapies.
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Table 1. Coeliac disease-associated HLA haplotypes and the overlap with 
other immune-related diseases
Haplotype Genotypes Diseases References
DR3-DQ2 DQ2.5-DQA1*0501-DQB1*0201DQ2.2-DQA1*0201-DQB1*0202
Systematic sclerosis 
Systemic lupus erythematosus 
Thyroid autoimmunity
[76-78]
DR4-DQ8 DQA1*0301-DQB1*0302 Type 1 diabetes [79]
Coeliac disease is associated with HLA
It is recognized that the haplotypes HLADQ2/DR3, HLA-DQ6/DR2 and 
HLA-DQ8/DR4 can provide increased susceptibility to autoimmune 
diseases [20–22]. Although many studies have attempted to determine 
the association between HLA class II molecules and susceptibility to 
-
hind these relationships because of: (i) differences in dietary or envi-
ronmental factors between diseases, (ii) genetic variation amongst hu-
man populations precluding the interpolation of results and (iii) the high 
linkage disequilibrium (LD) in the HLA region, which does not permit a 
clear dissection of the genes involved.
 There is, however, a clear and strong effect of certain HLA 
genes on CD (Table 1): almost all patients with CD express HLA-DQ2 
(DQ2.5-DQA1*0501-DQB1*0201 or DQ2.2-DQA1*0201-DQB1*0202) 
and almost all the remaining patients express HLA-DQ8 (DQA1*0301-
DQB1*0302) [23]. Depending on the number of HLA alleles present in an 
individual, the rate of disease development and the severity may vary. 
The highest risk for developing refractory CD (i.e. disease that does 
not respond to a gluten-free diet), for example, is observed in patients 
homozygous for DQ2.
 The main environmental factors that trigger the presentation of 
CD are prolamins, which are alcohol-soluble fractions found in cereals 
[24]. Prolamins (both glutenin and gliadin) are the principal component of 
gluten, which is responsible for the viscous elasticity of wheat dough, 
and the main toxic effects of gluten in CD are caused by gliadin [25]. The 
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close association between certain HLA alleles and the development 
HLA-DQ2 and HLA-DQ8 for the binding of gliadin-derived peptides, 
[26]; homozygosity for 
[27, 28]. The resulting im-
,/ћ IL4, IL6, IL8, IL10, IL15, IL17A, IL21, tumour necrosis factor 
71)њ and interferon ,1)ќ which cause intestinal mucosal atrophy 
and the consequent clinical manifestations [29].
 HLA genes may also play a role in the co-morbidity of CD with 
T1D, RA, CrD and UC. The HLA genes responsible for these other 
diseases can have different structural motifs that bind different epi-
tope triggers [22, 30]. For example, it is well known that the haplotypes 
DRB1*0301-DQA1*0501-DQB1*0201, DRB1*0405-DQA1*0301-
DQB1*0302, DRB1*0401-DQA1*0301-DQB*0302 and DRB1*0402-
DQA1*0301-DQB1*0302 carry a high risk for T1D in Caucasian 
populations (Table 1) [31]. In the case of RA, the major alleles are HLA-
DRB1*0401, DRB1*0404, DRB1*0405 and DRB1*0408 [30]. Howev-
er, in some populations, such as the Spanish and Indians, DQ8 and 
DR4 have been found to be predominantly associated with RA with 
an increased frequency of DQ7 amongst affected individuals [32]. The 
genotypes DR2 (DRB1*1501, DRB1*1502) and DR3 (DRB1*0103) are 
associated with the development of UC, and DR3 has been associated 
with the expression of CrD, whereas DR2 has been inversely associat-
ed with this disease [33].
 Although HLA haplotypes confer the highest genetic risk for 
CD, the fact that only about 3% of DQ2-/DQ8-positive individuals de-
velop the disease after exposure to gluten means that HLA is an es-
[34]. Hence, other genetic 
factors must be involved in the development of the disease to explain 
the familial clustering and the high concordance rate in monozygotic 
twins [35].
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Non-HLA genetic factors
involved in complex diseases, including CD. Basically, this approach 
makes use of families with affected pairs of siblings to identify chromo-
somal regions shared between these siblings at a rate above the mean 
of what is statistically expected [36] -
[37], followed by loci on chromosomes 2q33 and 19q13.1 [38]. Linkage 
studies have been highly successful in monogenic disorders but have 
not achieved the same success in complex diseases that are because 
of multiple risk variants with varying effect sizes.
 Candidate gene association is another approach that has been 
used in genetic studies of CD. The aim of this kind of study is to search 
for differences in the frequencies of genetic variants in patients, com-
pared with control individuals. Genetic association studies can focus 
on positional candidate genes from a linkage region, or on functional 
candidate genes selected based on the proposed disease pathology. 
Variants in the cytotoxic T-lymphocyte antigen 4 (CTLA4) gene [39] and 
myosin 1XB (MYO9B) [40] have been associated with CD by this ap-
from different populations remains limited.
 
advanced by genome-wide association (GWA) studies. This approach 
tests hundreds of thousands of single-nucleotide polymorphisms 
(SNPs) across the whole genome for association with a disease in 
hundreds or thousands of individuals [41]. GWA studies rely on the typ-
ically strong associations amongst SNPs located near each other on 
a chromosome, which tend to be inherited together more often than 
expected by chance (i.e. LD). As a consequence, only a subset of all 
SNPs needs to be genotyped and the remainder of the genetic infor-
mation can be inferred by imputation methods. Imputation allows one 
to compare data sets from different genotyping platforms with a com-
mon reference standard such as the international HapMap Project [42]; 
missing genotypes are predicted based on observed similarities [41].
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risk variants in the 4q27 region harbouring the IL2 and IL21 genes [43]. 
CCR3, 
3q25.33-IL12A, 2q12.1-IL18RAP, 1q31.2-RGS1, 12q24.12-SH2B3, 
6q25.3-TAGAP, 2p16.1-REL and 6q23.3-TNFAIP3 [44, 45] (Table 2). Most 
of these loci contain immune-related genes; in particular, genes impli-
cated in the control of the adaptive immune response. Together with 
IL2–IL21, these eight non-HLA loci explained 3–4% of the heritability 
of CD, in contrast to HLA-DQ2 alone, which explains 35%. A second 
GWA study revealed an additional 31 loci, which explain approximately 
another 5% of the heritability [45]. To date, 39 CD-associated loci that 
together contain 115 different genes have been found [45] (Table 2). 
Many of these SNP variants are also associated with other autoim-
mune diseases (Figure 2), which may point to interesting parallels in 
the pathogenesis of CD and these immune-related disorders.
 A challenge for all GWA studies is to move from a list of asso-
-
lying assumption is that the associated SNP genotyped in the study is 
in LD with the true disease-causing variant(s). If the causal SNP is also 
common, then it is likely to reside in close proximity to the genotyped 
SNP. Hypotheses can be postulated about genes within the LD regions 
relationships across implicated loci (GRAIL) and expression quan-
titative trait locus (eQTL) analyses can help to predict causal genes 
from associated loci. GRAIL is a statistical tool that uses text mining of 
GWA studies. When GRAIL was applied to the 115 genes comprising 
the 39 CD loci, the programme proposed genes involved in several im-
mune-related pathways as putative causal genes [46]. Twenty of the 39 
a nearby SNP (cis-eQTL), suggesting that these genes may be causal 
genes [45]. GRAIL and eQTL analyses are two different approaches, yet 
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Table 2. Non-HLA coeliac disease loci and their overlap with other immune-
related diseases
Loci Reported genes Overlapping immune-related diseasesa References
1q24.2 CD247 Rheumatoid arthritis Systemic sclerosis [45, 59, 81]
1q24.3 FASLG, TNFSF18, TNFSF4 Crohn's disease [45, 62] 












1p36.11 RUNX3 Unknown [45]
1p36.23 TNFRSF9, PARK7, ERFI1 Crohn's disease [45, 83]
1p36.32 PANK4, MMEL1, PCLCH2, HES5, TNFRSF14 Rheumatoid arthritis [45, 59] 
2q12.1 IL1RL1,IL18R1,IL18RAP, SLC9A4 Crohn's disease [44, 83]
2p14 PLEK, SPRED2 Rheumatoid arthritis [45, 59]




[45, 56, 59, 
83]
2q31.3 UBE2E3, ITGA4 Ankylosing spondylitis [45, 84]
2q33.2 CTLA4, ICOS Rheumatoid arthritisType 1 diabetes [45, 58, 59]
3q13.33 CDGAP, TMEM39A, KTELC1, CD80 Unknown [45]
3p14.1 FRMD4B Unknown [45]
3p21.31 CCR1, CCR2, CCRL2, CCR3, CCR5, CCR9, CXCR6, XCR1, LTF
Ulcerative colitis
Crohn's disease [44, 56]
3p22.3 TRIM71, CCR4,GLB1 unknown [45]
3q25.33 IL12A, SCHIP1 Multiple sclerosis [44, 85]
3q26.2 ARPM1, LRRC34, LRRC31, MYNN, LOC344657 Unknown [45]
3q28 LPP Unknown [44]
4q27 IL2, IL21, TENR, KIAA1109 Rheumatoid arthritisType 1 diabetes [43, 58, 59]
6q15 BACH2 Type 1 diabetesCrohn's disease [45, 58, 83]






6q25.3 TAGAP, RSPH3 Crohn's disease [44, 83]
6p25.3 IRF4 Unknown [45]
7p14.1 ELMO1 Unknown [45]





[45, 83, 85, 
86]
11q24.3 ETS1 Systemic lupus erythematosus [45, 89]
12q24.12 SH2B3 Type 1 diabetesRheumatoid arthritis [44, 58]
13q14.2 Intergenic Unknown [45]
14q24.1 ZFP36L1 Type 1 diabetes Crohn's disease [45, 58, 83]




[45, 56, 58, 
86]
17q21.31 MAPT, KIAA1267, LRRC37A, ARL17B, NSF, WNT3 Unknown [45]





[45, 58, 59, 
61]





Xp22.2 TLR8, TMSL3, TLR7, TMSB4X  Unknown [45]
a Immune-related diseases overlapping with CD according to the Catalogue of Published Genome-Wide 
Association Studies (http://www.genome.gov/26525384)
b IBD: inflammatory bowel disease
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two genes (IL18RAP and CCR3) were implicated by both approaches 
(Figure 2); these genes are thus strong candidates for causal genes.
 The current view of CD genetics is based on our knowledge of 
individual genes residing in the 39 known CD loci, our knowledge of 
the disease process, and circumstantial evidence based on GRAIL or 
eQTL analyses (see Table 2 and Table S1).
Shared and nonshared loci in immune-related dis-
eases
Because of the ubiquity of the immune system throughout the human 
body, any alteration in its regulation can manifest in other systems or 
through aetiologically related diseases. Consequently, autoimmune 
manifestations. In CD, the presentation of gluten epitopes to the im-
mune system initiates an immune response in the intestinal mucosa 
resulting in severe tissue damage. However, this is not the only mani-
festation of CD, which can also be accompanied by neurological, psy-
chiatric, thyroid, bone and obstetric problems [47, 48]. A similar situation 
occurs in T1D, which primarily involves the destruction of ћFHOOV in 
the pancreas, but can also present with alterations in the peripheral 
nervous system, altered intestinal permeability, retinopathy and glo-
merulonephritis [49]. Similarly, in RA, the primary manifestation involves 
the chronic and progressive destruction of diarthrodial joints, but in-
[50].
 From an immunological and cellular point of view, the dysregu-
lated processes involved in autoimmune diseases are generally com-
mon ones. Likewise, most if not all of these processes would ultimately 
result in activation of T cells. In this respect, it is interesting that dis-
-
conversion. For CD, the onset of symptoms often occurs in adulthood, 
despite seroconversion early in life and the presentation in children <3 
years of age [51]. For RA, UC and CrD, the peak age of presentation 
occurs between 30 and 50 years [52, 53]. For T1D, cases are often diag-
35
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Fig. 2. Shared and non-shared loci from GWA studies, for CD, T1D, RA, CrD and UC. Although 
each of these diseases has unique loci that can explain its individual characteristics, many of the 
loci are also shared and can be linked to a common immune aetiology. The genes shared between 
CD and other autoimmune diseases could play a role in the development of the immune response 
(light blue) and may be related to part of the common aetiology of these diseases. However, many 
of the genes found in the loci discovered so far do not have a clear role in the development of 
the immune response (orange). Several of these genes have been validated by data mining using 
gene relationships across implicated loci (GRAIL) (yellow circle) and through significant changes 
in transcript profiles discovered by the eQTL approach (purple star). This information has been 
derived from the Catalogue of Published Genome-Wide Association Studies (http://www.genome.
gov/26525384), the International HapMap Project [42], the UCSC Genome Browser [91] and 
GRAIL [92], [45, 46, 83].
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nosed in people below 15 years of age, with peak seroconversion at 
approximately 3 years of age [51].
 Despite their phenotypic diversity, autoimmune diseases can 
share both genetic and immunological mechanisms (Figure 2). GWA 
have provided evidence for shared genetic loci. Of the 39 known CD 
loci, approximately 64% are shared with at least one other autoimmune 
disease (Figure 2). Many of the shared loci are with T1D (10 loci), 
RA (9), CrD (17) and UC (5). These high numbers of shared loci may 
help to explain the common immunological processes that lead to the 
presentation of clinical signs and symptoms, and also the concurrent 
co-morbidity of multiple immune-related diseases in both individuals 
and families. Which disease leads to another in the case of concurrent 
diseases is a matter of debate. Given the well-known role of gluten in 
the development of CD, it is possible that one of it components de-
velops molecular mimicry leading to the presentation of another auto-
immune disease [54]. But as the environmental factors involved in the 
to investigate molecular mimicry [55].
 Genetic studies have enhanced our understanding of the pro-
cesses that may play a role in CD, in particular, and in autoimmunity, in 
general. An environmental trigger leads to the presentation of antigens 
binding to their receptors, induce intracellular signalling. One of the 
molecules involved in this signalling process is suppressor of cytokine 
signalling 1 (SOCS1), the gene for which is located in a region shared 
by CD, T1D and UC [45, 56, 57]. By contrast, SH2B3, which mediates the 
interaction between T-cell receptors and intracellular signalling path-
ways, is shared by CD, T1D and RA [45, 58, 59]. The SH2B3 complex in-
hibits the activation of nuclear factor of activated T cells, which acts by 
binding to DNA to regulate the expression of several cytokines, includ-
ing IL2. Moreover, it has been suggested that SH2B3 may play a role 
in protection from bacterial infections, because carriers of this risk vari-
37
Shared genetics in celiac disease and other immune-mediated diseases 
ant may have a strong activation of nucleotide-binding oligomerization 
domain containing 2 (NOD2) recognition. Further support for SH2B3 
being involved in bacterial protection comes from studies showing that 
the risk allele has undergone positive selection during evolution [60].
 The activation of signalling cascades generates many intracel-
lular processes, including the activation of transcription factors. One 
of the most well-studied transcription factors is nuclear factor kappa B 
1)ѣ% which is involved in the transcription of cytokines and genes 
related to the immune response. Hence, proper regulation of its ac-
tivity is essential for immune homeostasis. The REL gene is shared 
by CD, RA and UC and encodes for one of the members of the 1)ѣ%
transcription factor dimer [45, 56, 61]; alterations in REL lead to increased 
expression of 1)ѣ% in the nucleus and, therefore, to a high level of 
expression of target genes for this protein. CD and RA share TNFAIP3, 
which acts as an inhibitor of 1)ѣ% and as a modulator of the signalling 
through TLR4 [45, 59]. In murine models, it was found that silencing of 
the Tnfaip3 gene may lead to hyperactivation of cytotoxic T cells and 
inhibition of regulatory T cells. The protein product of the TNFRSF14 
gene, another gene that is shared between CD and RA, serves as a 
co-stimulator for T-cell activation by activating 1)ѣ% through TNF-re-
lated cytokines [45, 59].
 T and B lymphocytes have a role as end effectors of the im-
mune response. These effector functions will largely depend on the 
quality and intensity of the response. In this respect, CTLA4 (which 
is shared by CD, T1D and RA) and ICOSLG (shared by CD and CrD) 
may act as regulators of proliferation and activation of T lymphocytes 
(Fig. 3) [45, 58, 61, 62]. Normally, 71)њ increases the level of ICOSLG in B 
cells and monocytes, and further increase in T-lymphocyte proliferation 
and cytokine production is dependent on IL2, ,1)ќ and IL10. CTLA4 
normally acts as an inhibitor of T-cell response by interfering with the 
TCR signalling pathway.
 Protein tyrosine phosphatise, nonreceptor type 2 (PTPN2) 
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response in T cells. The PTPN2 gene is associated with the occur-
rence of CD, CrD and T1D, suggesting that it is involved in the overlap-
ping pathways of these immune-related diseases. A study with Ptpn2 
knockout mice showed that the absence of this gene leads to diarrhoea 
and progressive weight loss [63]. These studies highlight that PTPN2 is 
another potential gene of interest in immune-related diseases.
 The genes discovered so far that are shared by CD and T1D, 
RA, UC or CrD can be grouped according to their physiological func-
tion, thereby providing insight into their role in the disease processes. 
When interpreting these results, it is also essential to take into account 
the intricate web of interactions and functions that a single protein can 
have, as proteins often have more than one function. From a genetic 
point of view, the loci that are not shared between diseases are also 
interesting as they may point to unique pathophysiological processes 
in each disease.
What is the value of identifying shared genetics?
At present, it is known that CD shares loci with at least four other im-
mune-related diseases (Figure 2), which highlights the overlap be-
tween these diseases and suggests common immunological pathways 
that could be targeted for treating them. Using information from shared 
shared by all immune-related diseases, in addition to a disease-spe-
-
cal tool for planning therapeutic intervention studies. The accuracy of 
immunological factors are characterized and the gene–environmental 
contribution to disease becomes clearer [19].
 The presence of shared genetics raises the possibility that new 
therapeutic interventions can be developed rationally, based on a clear 
understanding of disease pathogenesis. In addition, existing drugs for 
one disease might be useful for targeting another, if the pathway be-
39
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ing targeted is shared between the diseases. TNF plays an important 
Some autoimmune diseases, such as RA and CrD, can be associated 
with abundant levels of TNF. The TNF receptor 2 is involved in the 
mobilization and nuclear entry of the transcription factor 1)ѣ% and has 
been suggested as a new target for drug development in autoimmune 
diseases. Because of polymorphism in the TNF receptor 2 gene, some 
defects in the TNF receptor 2 pathway have been implicated in the 
pathology of autoimmune diseases. Currently, anti-TNF therapies are 
being used for treating RA and CrD [64].
 The IL12/IL23 inhibitor sTA-5326 has been used to treat RA 
and CrD. This drug downregulates – at the transcriptional level – the 
p35 subunit of IL12 and the p40 subunit of IL12 and IL23, thereby in-
hibiting the production of both ILs [65]. Because IL12 also plays a role 
in activating natural killers cells and T lymphocytes, and because other 
genes of the IL12 and IL23 pathways are also associated with sever-
al autoimmune diseases, sTA-5326 might be a potential treatment for 
CD. However, there are also genetic loci that determine an individual’s 
response to treatment. The effectiveness of anti-TNF agents, for ex-
ample, varies between individuals [65,66]. Knowing which genetic factors 
determine this might be useful for selecting patients who are likely to 
respond to treatment.
 It has been known since the late 1940s that adherence to a 
gluten-free diet is an effective treatment for CD; however, this diet 
can also prevent the development of other autoimmune disorders [67]. 
Fuchtenbusch et al. showed that exposure to dietary gluten very early 
in life in offspring of parents with T1D is associated with an increased 
risk of developing islet antibodies; the authors suggested that remov-
al of dietary gluten should be tested as early as possible in children 
with an increased risk of islet autoimmunity, i.e. before an immune re-
sponse to islet antigens is established [68]. In addition, a gluten-free diet 
can prevent diabetes in nonobese diabetic (NOD) mice [69].
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CD develops because of a lack of oral tolerance to dietary gluten and 
apart from removing gluten from the diet, it might also be possible to 
induce tolerance to gluten. The PreventCD study (http://www.prevent-
celiacdisease.com) is testing the induction of oral gluten tolerance by 
introducing small quantities to infants at high risk of developing CD 
during the period of breastfeeding; high-risk individuals are those pos-
this intervention works, it might also reduce the risk of other immune-re-
lated diseases and could be applied more widely beyond those infants 
at high risk for developing CD. The induction of oral tolerance is prob-
factors are currently unknown.
 Immune-related diseases can be triggered by different environ-
mental factors, including infectious agents. Some of these agents could 
also be shared by immune-related diseases, although the same agent 
might have an opposite effect in different diseases, e.g. inducing one 
but protecting against another. The development of an autoimmune 
disease after infection is expected to occur only in genetically suscep-
tible individuals, and a shared genetic background might explain why 
only a subgroup of individuals develops autoimmunity after infection 
[70]. In CD, for example, it has been suggested that rotavirus infections 
can increase the risk of disease [7]. Rotaviruses have also been associ-
ated with exacerbation of pancreatic islet autoimmunity in humans and 
shown to promote insulitis and exacerbate diabetes in NOD mice [71]. 
HCV has also been associated with CD, CrD and thyroiditis [70, 72]. Cer-
tain immune-related genetic factors, such as CTLA4, could be involved 
in the susceptibility to HCV [73]
agents suggest that the same environmental factor, together with a 
common genetic background, could be shared by different immune-re-
lated diseases.
 Another important factor might be the host microbiome. Only 
recently has it become possible to investigate the microbiome, but it 
is clear that its composition and function are largely driven by the host 
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genome. Alterations in the microbiome can occur as a result of, for 
example, infection or disease pathology. It would be interesting to de-
termine whether shared genetic factors also result in a partly shared 
gut microbiota, their metabolic activities and their interactions with the 
mucosal immune system [74].
Future perspectives
The GWA studies conducted so far have taken into account the LD 
present in the genome. This type of approach has provided much infor-
previously reported loci from linkage and case–control studies. Never-
theless, it is still not possible to explain a large proportion of the genet-
ic component of CD and other immune-related diseases. In addition 
to more GWA studies within and across diseases, different strategies 
such as whole genome or exome sequencing need to be employed to 
identify the full genetic heritability of these immune-related diseases. 
The sequencing techniques will not only identify more common vari-
ants associated with disease but may also reveal additional rare vari-
ants or even private mutations that cause disease. Another option will 
be to use targeted arrays that are enriched for both common and rare 
variants, such as the immunochip.
 The immunochip consists of approximately 200000 markers, 
but is designed to contain only SNPs in about 200 genes known to be 
associated with an immune-related disease. One of the advantages of 
the immunochip is that it includes many more markers in both coding 
and regulatory regions of genes, as well as variants with very low fre-
quencies. The markers located in the regulatory regions will be useful 
to result in the discovery of new variants for each disease and many 
more variants shared by autoimmune diseases. The immunochip will 
be used by the international iChip consortium studying 11 different 
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immune-related diseases, which will allow large-scale meta-analyses 
across diseases. As collecting many more samples for each disease 
will form a bottleneck for performing new genetic studies, combining 
CD) meta-analyses of GWA studies were successfully performed [75, 76]. 
A study in which GWA analyses of CD and RA were combined revealed 
eight new shared loci for these two diseases, in addition to the six that 
were already known. These results clearly show that combining differ-
 Despite the advances in technology and statistical analyses, 
a proper characterization of the phenotype is still important. CD and 
-
types which are easy to determine, particularly because the pheno-
types can cover a broad range of symptoms. This means that it might 
be necessary to establish new phenotypes based on measurable and 
presence or levels of auto-antibodies, the molecular characteristics of 
cells involved in the immune response, or levels of transcription of cer-
tain genes or groups of genes.
 Future studies should also take the role of environmental factors 
into careful consideration. Thus, it will be necessary to carry out strict 
populations that carry the greatest risk for autoimmune diseases. Be-
cause most genetic studies take advantage of patient cohorts that are 
available, the data will have to be collected retrospectively, although it 
would be more reliable to collect data prospectively on both disease 
outcomes and exposure to environmental factors. Such an approach 
could yield insight into the environmental factors that may be related 
to the presentation of CD, as well as other autoimmune diseases, and 
could be useful for determining behaviours and habits that have not 
disease.
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